Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thyroid Stunning from I-123
NCT02278198Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2012
- Primary completion
- Sep 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iodine-123 in differentiated thyroid cancer (DTC), sponsored by University of Colorado Denver. Primary endpoint: Difference in uptake of I-123 in the thyroid remnant in the neck in the two imaging studies at 11 days. Started Nov 2012; status: completed.
02
Drugs
iodine-123
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT02278198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278198.